Zentalis Pharmaceuticals, Inc. ZNTL
1.78 USD -0.07 (-3.78%)
At closeNov 4, 2026, 5:16 AM EST
1.84 +0.06 +3.37%
Pre-market · Nov 4, 5:16 AM ET
1.75 Day range 1.96
1.21 52-week range 6.95
- YTD
- +31.85%
- 1 year
- +23.61%
News
globenewswire.com Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
globenewswire.com Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
benzinga.com Zentalis Pharmaceuticals Presents Data From Its Interim Analysis Of DENALI Part 1b Trial At ESMO Congress 2026 Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven…
globenewswire.com Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
defenseworld.net HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday, Marketbeat.com reports.…
benzinga.com HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy and maintains $10 price target.
globenewswire.com Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
defenseworld.net Johnson & Johnson (NYSE:JNJ) & Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head-To-Head Contrast Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) and Johnson and Johnson (NYSE: JNJ - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the…
defenseworld.net Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL) Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
defenseworld.net Leerink Partners Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock analysts at Leerink Partners started coverage on shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) in a report released on Monday, MarketBeat reports. The firm set an…
benzinga.com Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8 Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.
globenewswire.com Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
benzinga.com This Small Biotech's Cancer Drug Could Reach $1.3 Billion In Peak Sales Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) received a bullish initiation from William Blair on Tuesday, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug,…
seekingalpha.com Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL BlackRock Inc. acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) during the second quarter, according to the company in its most recent filing with the Securities and Exchange…
globenewswire.com Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
globenewswire.com Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…
seekingalpha.com Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target…
globenewswire.com Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an…
globenewswire.com Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an…
globenewswire.com Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an…
globenewswire.com Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 Enrollment completed in Part 2a and 2b of the DENALI trial; Part 2c is enrolling DENALI…
globenewswire.com Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…